{"denoms":[{"counts":[{"groupId":"BG000","value":"951"},{"groupId":"BG001","value":"950"},{"groupId":"BG002","value":"1901"}],"units":"Participants"}],"groups":[{"description":"Zoledronic acid 4 mg by intravenous injection with a subcutaneous denosumab placebo once every 4 weeks","id":"BG000","title":"Zoledronic Acid"},{"description":"Denosumab 120 mg subcutaneously with an intravenous zoledronic acid placebo once every 4 weeks","id":"BG001","title":"Denosumab"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.4","value":"71.0"},{"groupId":"BG001","spread":"8.7","value":"70.5"},{"groupId":"BG002","spread":"8.6","value":"70.8"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"951"},{"groupId":"BG001","value":"950"},{"groupId":"BG002","value":"1901"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"810"},{"groupId":"BG001","value":"829"},{"groupId":"BG002","value":"1639"}]}],"title":"White or Caucasian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"38"},{"groupId":"BG002","value":"73"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"57"},{"groupId":"BG001","value":"45"},{"groupId":"BG002","value":"102"}]}],"title":"Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"48"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}],"title":"Native Hawaiian or Other Pacific Islander"},{"categories":[{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"37"}]}],"title":"Other"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"145"},{"groupId":"BG001","value":"145"},{"groupId":"BG002","value":"290"}]}],"title":"PSA level < 10 ng/mL"},{"categories":[{"measurements":[{"groupId":"BG000","value":"806"},{"groupId":"BG001","value":"805"},{"groupId":"BG002","value":"1611"}]}],"title":"PSA level ≥ 10 ng/mL"}],"paramType":"NUMBER","title":"Prostate-Specific Antigen (PSA) Stratification Factor","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"231"},{"groupId":"BG001","value":"232"},{"groupId":"BG002","value":"463"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"720"},{"groupId":"BG001","value":"718"},{"groupId":"BG002","value":"1438"}]}],"title":"No"}],"paramType":"NUMBER","title":"Previous Skeletal-Related Event (SRE) Stratification Factor","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"132"},{"groupId":"BG001","value":"132"},{"groupId":"BG002","value":"264"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"819"},{"groupId":"BG001","value":"818"},{"groupId":"BG002","value":"1637"}]}],"title":"No"}],"description":"Defined as within 6 weeks before randomization","paramType":"NUMBER","title":"Current Prostate Cancer Chemotherapy Stratification Factor","unitOfMeasure":"Participants"}]}